Nuvectis Pharma, Inc. (NVCT) vs ProKidney Corp. (PROK)
A side-by-side comparison of Nuvectis Pharma, Inc. and ProKidney Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NVCT
Nuvectis Pharma, Inc.
$19.92HealthcareDelayed quote: Oct 6, 2026, 3:44 PM EDT
PROK
ProKidney Corp.
$1.58HealthcareDelayed quote: Oct 6, 2026, 3:45 PM EDT
Total return — NVCT vs PROK
growth of $100 · dividends reinvested · last 5yNVCT +558.2% (+45.8%/yr)PROK -84.0% (-30.7%/yr)NVCT compounded faster over this window
Log scale — wide-divergence pair
NVCT PROK
NVCT vs PROK: by the numbers
- •PROK is the larger company ($531M vs $529M market cap).
- •Both run net losses; NVCT's is the smaller (0.00% vs -10599.76% net margin).
Metrics side by side
Valuation
| Metric | NVCT | PROK |
|---|---|---|
| P/S ratio | N/A | 648.99 |
| P/B ratio | 58.20 | N/A |
Profitability
| Metric | NVCT | PROK |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -18477.83% |
| Net margin | 0.00% | -10599.76% |
| ROE | -306.61% | N/A |
| ROIC | -317.86% | -78.31% |
Growth (annualized)
| Metric | NVCT | PROK |
|---|---|---|
| Total return CAGR (5Y) | N/A | -30.65% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.